Drug Trial Radar · NCT06623162
Sasanlimab As Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized Muscle Invasive Bladder Cancer Patients
Last checked: Nov 19, 2026Latest source record: Oct 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Dec 2024
Primary completion
Dec 2026
Study completion Dec 2027
Sponsor
- Lead sponsor
- Fundación de investigación HMAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- MFAR Clinical Research S.L.; Hospital Universitario 12 de Octubre
- First posted
- Oct 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Selective Bladder-Sparing Trial with Sasanlimab as Maintenance Treatment Based On Clinical Response To Neoadjuvant Treatment In Molecularly Categorized Muscle Invasive Bladder Cancer Patients
Conditions
- Mibc
- Muscle Invasive Bladder Cancer
Interventions
gemcitabine + cisplatineDrug
4 cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the bladder-intact overall survival at 12 months after the first dose of sasanlimab. Bladder-intact overall survival is defined as the time from initiation of sasanlimab treatment until death or cystectomyTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hm Sanchinarro
Madrid, Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.